04/16/2015 On April 16, 2015, the U.S. District Court for the District of New Jersey denied Otsuka’s Motion for a Temporary Restraining Order, finding that Apotex Inc. and others are ‘permitted to launch their generic aripiprazole products after April 20, 2015.’ In an extraordinarily thorough and well-reasoned 101-page decision , Chief Judge Simandle found that Otsuka failed tocarry its burden on, among other things, claim construction, direct infringement, induced infringement, irreparable harm, causal nexus, and invalidity. The RMMS team included William Rakoczy, Deanne Mazzochi, Joseph Jaros, Jeffrey Marx, and Neil McLaughlin.
This victory demonstrates that RMMS has the depth and resources to defeat 11th-hour requests for injunctive relief and continues to place RMMS at the forefront of generic challenges to brand pharmaceutical patents.